前列地尔联合贝前列素钠序贯治疗早期糖尿病肾脏病的临床观察  

Clinical Observation of Alprostadil Combination with Beraprost Sodium Sequential Therapy in the Treatment of Early Diabetic Renal Disease

作　　者：王晓露[1] 曾芙蓉[1] 李凡[1] 钟倩[1] 高俊杰[1] 孙芃芃[1] 

机构地区：[1]鞍山市中心医院内分泌科,114001

出　　处：《中国卫生标准管理》2015年第29期118-119,共2页China Health Standard Management

摘　　要：目的观察前列地尔联合贝前列素钠序贯治疗早期糖尿病肾脏病的有效性、安全性。方法 108例2型糖尿病早期肾脏病患者,随机分为3组,前列地尔组38例,前列地尔联合贝前列素钠序贯治疗组34例,丹参川芎组36例,均10 ml/d,2周,检测治疗前后尿白蛋白/肌酐比值、血尿素氮、血肌酐、纤维蛋白原、凝血酶原时间(PT)、血小板的变化。结果三组治疗前后前列地尔联合贝前列素钠序贯治疗组白蛋白/肌酐比值下降更明显(P<0.01);丹参川芎组治疗前后有所变化但无统计学意义(P>0.05);凝血酶原时间(PT)、血小板的变化无统计学差异(P>0.05)。结论前列地尔联合贝前列素钠序贯治疗早期糖尿病肾脏病疗效明显高于短期前列地尔单药治疗,疗效更好且无出血倾向,安全性好。Objective To observe the effect of alprostadil combined with beraprost sodium sequential treatment of early diabetic kidney disease is effective, safety. Methods 108 cases of type 2 diabetes early kidney disease patients, were randomly assigned to 3 groups, forefront of E1 group, n = 38, the forefront of alprostadil combined with b FGF（sodium sequential therapy group, n = 34, Salvia Chuanxiong group n = 36 cases were seed into, 2 weeks, were detected before and after treatment of urinary albumin / creatinine ratio, blood urea nitrogen, blood creatinine, fibrinogen, prothrombin time（PT）, platelet changes. Results Three groups before and after treatment in the forefront of alprostadil combined with b FGF（sequential sodium treatment group albumin / creatinine ratio decreased more obviously（P 0.01）; Salvia Chuanxiong group before and after treatment change but there was no statistical significance（P 0.05）; the changes of prothrombin time（PT）, platelet no statistical difference（P 0.05）. Conclusion The forefront of alprostadil combined with b FGF prime sodium sequential therapy in the treatment of early diabetic kidney disease curative effect is significantly higher than that of short-term alprostadil monotherapy, better curative effect and no bleeding tendency and safety.

关 键 词：早期糖尿病肾脏病 前列地尔 贝前列素钠 

分 类 号：R969[医药卫生—药理学]